Novel cystine knot protein and materials and methods for making it
OwnerPaul O. Sheppard, Si Lokinventors
Life of this patent
Estimating the term…
Abstract
The present invention relates to polynucleotide and polypeptide molecules for zsig51, a novel member of the cystine knot family of polypeptides. The polypeptides comprise a sequence of amino acid residues that is at least 80% identical in amino acid sequence to residues 1 through 106 of SEQ ID NO:2. The invention further provides therapeutic and diagnostic methods utilizing the polynucleotides, polypeptides, and antagonists of the polypeptides.
Claims35
An isolated polypeptide comprising at least 15 consecutive amino acid residues of SEQ ID NO:2.
An isolated polypeptide that is at least 80% identical in amino acid sequence to residues 1 through 106 of SEQ ID NO:2, said polypeptide comprising cysteine residues at positions corresponding to residues 8, 34, 38, 66, 96, and 98 of SEQ ID NO:2;
- a glycine residue at a position corresponding to residue 36 of SEQ ID NO:2;
- and beta strand-like regions corresponding to residues 9-17, 29-34, 38-43, 59-64, 67-71, and 90-95 of SEQ ID NO:2.
An isolated protein comprising a first polypeptide complexed to a second polypeptide, wherein said first polypeptide is at least 80% identical in amino acid sequence to residues 1 through 106 of SEQ ID NO:2 and comprises cysteine residues at positions corresponding to residues 8, 34, 38, 66, 96, and 98 of SEQ ID NO:2;
- a glycine residue at a position corresponding to residue 36 of SEQ ID NO:2;
- and beta strand-like regions corresponding to residues 9-17, 29-34, 38-43, 59-64, 67-71, and 90-95 of SEQ ID NO:2, and wherein said protein modulates cell proliferation, differentiation, or metabolism.
An expression vector comprising the following operably linked elements:
- a transcription promoter;
- a DNA segment encoding a polypeptide that is at least 90% identical in amino acid sequence to residues 1 through 106 of SEQ ID NO:2, said polypeptide comprising cysteine residues at positions corresponding to residues 8, 34, 38, 66, 96, and 98 of SEQ ID NO:2;
- a glycine residue at a position corresponding to residue 36 of SEQ ID NO:2;
- and beta strand-like regions corresponding to residues 9-17, 29-34, 38-43, 59-64, 67-71, and 90-95 of SEQ ID NO:2;
- and
- a transcription terminator.
A method for detecting a genetic abnormality in a patient, comprising:
- obtaining a genetic sample from a patient;
- incubating the genetic sample with a polynucleotide comprising at least 14 contiguous nucleotides of SEQ ID NO:1 or the complement of SEQ ID NO:1, under conditions wherein said polynucleotide will hybridize to complementary polynucleotide sequence, to produce a first reaction product;
- comparing said first reaction product to a control reaction product, wherein a difference between said first reaction product and said control reaction product is indicative of a genetic abnormality in the patient.
An oligonucleotide probe or primer comprising 14 contiguous nucleotides of a polynucleotide of SEQ ID NO:4 or a sequence complementary to SEQ ID NO:4.
Dependencies are inferred from the claim text.